Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + CapeOX after SCRT for Locally Advanced Rectal Cancer
NCT05086627Phase 2Completed
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Sep 2021
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in rectal cancer (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Pathological Complete Response Rate. Started Sep 2021; status: completed.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05086627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05086627.